Literature DB >> 26961321

When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month.

M Torres-Ferrús1,2, M Quintana2, J Fernandez-Morales1, J Alvarez-Sabin2, P Pozo-Rosich1,2.   

Abstract

Introduction According to the IHCD-3β classification, chronic migraine (CM) is headache occurring on 15 or more days/month. Episodic migraine (EM) can be divided into low frequency (LFEM) and high frequency (HFEM) depending on the headache days suffered per month. Methods We performed a clinical comparison of migraine characteristics according to monthly headache days suffered. Patients were divided into three groups: LFEM (1-9 headache days/month), HFEM (10-14 headache days/month) and CM (≥15 headache days/month). Results The analysis included 1109 patients. Previously reported differences between EM and CM were replicated. However, there were three times more clinical differences between LFEM and HFEM than between HFEM and CM (15 vs. 6). A new model that takes 10 headache days as a cut-off value for CM would have a minimally higher predictive capacity (72.8%) and no statistical differences (71.8%) when comparing it to the current classification. Conclusions HFEM patients have few clinical differences compared with CM patients. This includes the poor outcomes regarding headache-related disability and impact on daily life. According to these findings, neurologists and headache specialists should consider that the emotional and functional impact in HFEM patients could be as disabling as in those with CM.

Entities:  

Keywords:  Headache; MIDAS; chronic migraine; disability; migraine

Mesh:

Year:  2016        PMID: 26961321     DOI: 10.1177/0333102416636055

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  12 in total

Review 1.  Cognition and Cognitive Impairment in Migraine.

Authors:  Raquel Gil-Gouveia; Isabel Pavão Martins
Journal:  Curr Pain Headache Rep       Date:  2019-09-11

2.  Three Dimensions of Association Link Migraine Symptoms and Functional Connectivity.

Authors:  Samuel R Krimmel; Danielle D DeSouza; Michael L Keaser; Bharati M Sanjanwala; Robert P Cowan; Martin A Lindquist; Jennifer A Haythornthwaite; David A Seminowicz
Journal:  J Neurosci       Date:  2022-06-29       Impact factor: 6.709

Review 3.  Neurobiology of migraine progression.

Authors:  Wanakorn Rattanawong; Alan Rapoport; Anan Srikiatkhachorn
Journal:  Neurobiol Pain       Date:  2022-06-09

4.  Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.

Authors:  Raffaele Ornello; Alfonsina Casalena; Ilaria Frattale; Valeria Caponnetto; Amleto Gabriele; Giannapia Affaitati; Maria Adele Giamberardino; Maurizio Assetta; Maurizio Maddestra; Fabio Marzoli; Stefano Viola; Davide Cerone; Carmine Marini; Francesca Pistoia; Simona Sacco
Journal:  J Headache Pain       Date:  2020-08-15       Impact factor: 7.277

5.  Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme.

Authors:  Kaname Ueda; Wenyu Ye; Louise Lombard; Atsushi Kuga; Yongin Kim; Sarah Cotton; James Jackson; Tamas Treuer
Journal:  J Headache Pain       Date:  2019-06-07       Impact factor: 7.277

Review 6.  From transformation to chronification of migraine: pathophysiological and clinical aspects.

Authors:  M Torres-Ferrús; F Ursitti; A Alpuente; F Brunello; D Chiappino; T de Vries; S Di Marco; S Ferlisi; L Guerritore; N Gonzalez-Garcia; A Gonzalez-Martinez; D Khutorov; M Kritsilis; A Kyrou; T Makeeva; A Minguez-Olaondo; L Pilati; A Serrien; O Tsurkalenko; D Van den Abbeele; W S van Hoogstraten; C Lampl
Journal:  J Headache Pain       Date:  2020-04-29       Impact factor: 7.277

Review 7.  Interventional Procedures in Episodic Migraine.

Authors:  Brian M Plato; Mandy Whitt
Journal:  Curr Pain Headache Rep       Date:  2020-11-12

8.  Should We Adapt the Prescription Criteria for Specific Treatments for Migraine Due to the COVID-19 Pandemic?

Authors:  Jesús Porta-Etessam; Nuria Gonzalez-Garcia; Jordi A Matias-Guiu; Paloma Montero-Escribano; Jorge Matías-Guiu
Journal:  Headache       Date:  2020-06-15       Impact factor: 5.311

9.  European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA).

Authors:  Simona Sacco; Mark Braschinsky; Anne Ducros; Christian Lampl; Patrick Little; Antoinette Maassen van den Brink; Patricia Pozo-Rosich; Uwe Reuter; Elena Ruiz de la Torre; Margarita Sanchez Del Rio; Alexandra J Sinclair; Zaza Katsarava; Paolo Martelletti
Journal:  J Headache Pain       Date:  2020-06-16       Impact factor: 7.277

10.  Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.

Authors:  Raffaele Ornello; Alfonsina Casalena; Ilaria Frattale; Amleto Gabriele; Giannapia Affaitati; Maria Adele Giamberardino; Maurizio Assetta; Maurizio Maddestra; Fabio Marzoli; Stefano Viola; Davide Cerone; Carmine Marini; Francesca Pistoia; Simona Sacco
Journal:  J Headache Pain       Date:  2020-04-07       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.